




Aerie Pharmaceuticals  
Investor Relations Department  
135 US Highway 206, Suite 15  
Bedminster, NJ 07921  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#) 

#### NASDAQ: AERI

Last Trade:	54.55
Trade Time:	10:37 AM ET Jul 28, 2017
Change:	0.35  (+0.646%)
Day Range	54.09 - 55.05
52-Week Range	16.61 - 59.50
Volume	39,332


Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

We are a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.

Glaucoma is a progressive and highly individualized disease, in which elevated levels of intraocular pressure, or IOP, are associated with damage to the optic nerve, which results in irreversible vision loss and potentially blindness. Patients may suffer the adverse effects of glaucoma across a wide range of IOP levels. Our product candidates, Rhopressa™ (netarsudi... [\(more\)](#))

## Stock Performance



## Press Releases [\[ View all \]](#)

- Jul 26, 2017*  
[Aerie Pharmaceuticals to Announce Second Quarter 2017 Financial Results and Host Conference Call on Tuesday, August 1, 2017](#)
- Jul 25, 2017*  
[Aerie Pharmaceuticals Announces Appointment of Richard A. Halprin as Director of Professional Affairs](#)
- Jul 19, 2017*  
[Aerie Pharmaceuticals Reports Positive Roclatan™ \(netarsudil/latanoprost ophthalmic solution\) 0.02%/0.005% Phase 3 12-month Topline Safety Results](#)
- Jun 1, 2017*  
[Aerie Pharmaceuticals to Present at Two Investor Conferences in June](#)
- May 26, 2017*  
[Aerie Pharmaceuticals Raises \\$125 Million in ATM Sales and Upsized Follow-On Offering](#)

## Upcoming Events [\[ View all \]](#)

- Aug 1, 2017 5:00 PM ET*  
[Aerie Pharmaceuticals, Inc. Second Quarter 2017 Earnings Call](#)
- Financials [\[ View all \]](#)**
- [First Quarter Financial Results](#)
- Mar 9, 2017*  
[Annual Report \(10-K\)](#)
- Apr 27, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- May 3, 2017*  
[Quarterly Report \(10-Q\)](#)
- Nov 3, 2016*  
[Quarterly Report \(10-Q\)](#)
- Aug 4, 2016*  
[Quarterly Report \(10-Q\)](#)